TSG-RESCUE™

About Divincell

Divincell is a private, preclinical-stage biotech pioneering a novel peptide-based nanoparticle (PEP-NP™) platform for the targeted systemic delivery of therapeutic RNAs. The company is developing a pipeline of RNA-based therapies targeting tumor suppressor gene restoration, oncogene editing, and in vivo CAR-T cell generation, primarily for oncology. With leadership boasting decades of experience in nanomedicine and drug delivery, Divincell is positioning itself to address key challenges in RNA therapeutics, such as precise extrahepatic targeting and repeatable administration, though it remains pre-revenue and faces significant development and competitive risks.

About Aanastra

Aanastra is pioneering a novel approach to RNA therapeutics with its proprietary PEP-NP™ peptide-based delivery platform, designed to solve the critical industry challenge of targeted, systemic, and repeatable RNA delivery beyond the liver. The company's pipeline is focused on three high-impact, platform-enabled strategies: restoring tumor suppressor function (TSG-RESCUE™), generating CAR-T cells in vivo (PEP-CAR™), and editing/deleting oncogenes (ONCOEDIT™). As a private, pre-revenue company, Aanastra is positioned to address large unmet needs in oncology and autoimmune diseases, though it faces significant technical and competitive risks inherent to the novel drug delivery and gene modulation space.

Therapeutic Areas